临床试验/NCT06448026

NCT06448026招募中2 期

Cemiplimab and Cetuximab Prior Salvage Surgery in Patients With Recurrent Oral Cavity and HPV-negative Oropharyngeal Squamous Cell Carcinoma

M.D. Anderson Cancer Center1 个研究点分布在 1 个国家目标入组 17 人开始时间: 2024年11月21日最近更新: 2026年7月30日

适应症

干预措施

试验速览

阶段: 2 期
状态: 招募中
发起方: M.D. Anderson Cancer Center
入组人数: 17
试验地点: 1
主要终点: Safety and adverse events (AEs)

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

To learn if giving cemiplimab and cetuximab before salvage surgery can help to control recurrent oral cavity squamous cell carcinoma.

详细描述

Primary Objective:

- Primary Objectives To evaluate the clinical efficacy, defined as overall response rate, of cemiplimab combined with cetuximab in patients with recurrent oral cavity and HPV-negative oropharynx squamous cell carcinoma.

Secondary Objective:

-To evaluate other markers of clinical efficacy (pathological response rates, objective response rate per RECIST, overall survival) and safety.

Exploratory Endpoints

研究设计

研究类型: Interventional
分配方式: Na
干预模型: Single Group
主要目的: Treatment
盲法: None

入排标准

年龄范围: 18 Years 至 —（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•Subjects .18 years with histology-proven locoregionally recurrent oral cavity squamous cell carcinoma or HPV-negative OPSCC
•HPV testing is required only in oropharyngeal sites and must be negative
•Amenable to salvage surgery
•Disease recurrence at least 3 months after completion of curative-intent therapy, which must include at least surgery and post operatory radiation. Previous systemic therapy is the curative-setting is not required but allowed (e.g., neoadjuvant chemotherapy, concurrent chemotherapy).
•Measurable disease per RECIST 1.1
•Performance status ECOG of 0 or 1
•Willing to undergo baseline (if archival tumor specimen is not available) and on-treatment biopsy for correlative studies
•Laboratory measurements, blood counts:
•Hemoglobin ≥ 9 g/dL. Red blood cell transfusions are permitted to meet the hemoglobin inclusion criteria
•Absolute neutrophil count ≥ 1 x 109/mL
•Platelets ≥ 80 x 109/mL
•Laboratory measurements, renal function:
•a) Creatinine clearance ≥ 30 mL/min as assessed by the Cockcroft-Gault equation
•Laboratory measurements, hepatic function:
•AST and ALT ≤ 3 x ULN
•Total bilirubin ≤ 1.5 x ULN or ≤ 3.0 x ULN and primarily unconjugated if subject has a documented history of Gilbert's syndrome or genetic equivalent.
•Female subjects with reproductive potential must practice two effective contraceptive measures for the duration of study drug therapy and for at least 120 days after completion of study therapy. The two birth control methods can be either two barrier methods or a barrier method plus a hormonal method to prevent pregnancy. The following are considered adequate barrier methods of contraception: diaphragm, condom, copper intrauterine device, sponge, or spermicide. Appropriate hormonal contraceptives will include any registered and marketed contraceptive agent that contains an estrogen and/or a progestational agent (including oral, subcutaneous, intrauterine, or intramuscular agents).
•Male participants who are sexually active with women with reproductive potential must agree to use contraception for the duration of treatment and for at least 90 days after completion of study therapy.

排除标准

•Disease recurrence within 3 months after completion of definitive treatment (including surgery, post operatory, systemic therapy)
•Distant metastatic disease (M1), visceral and/or distant nodal
•Prior treatment with an t immune checkpoint inhibitor agent in the curative setting is allowed if over 1 year from the date of completion (last dose)
•Subjects with a condition requiring corticosteroid therapy (>10 mg prednisone/day or equivalent) within 14 days of the first dose of study drug.
•Exceptions: Physiologic replacement doses are allowed even if they are >10 mg of prednisone/day or equivalent, as long as they are not being administered for immunosuppressive intent. Inhaled or topical steroids are permitted, provided that they are not for treatment of an autoimmune disorder.
•Subjects with active, known, or suspected autoimmune disease that has required systemic therapy within 5 years of the projected enrollment date. Exceptions: Subjects with vitiligo, type I diabetes mellitus, and endocrinopathies (including hypothyroidism due to autoimmune thyroiditis) only requiring hormone replacement, childhood asthma that has resolved, or psoriasis that does not require systemic treatment are permitted.
•History of interstitial lung disease (eg, idiopathic pulmonary fibrosis, organizing pneumonia) or active, noninfectious pneumonitis that required immune-suppressive doses of glucocorticoids to assist with management.
•Recipient of a solid organ transplant (other than corneal transplants)
•Prior allogeneic stem cell transplantation, or autologous stem cell transplantation
•History of previous malignancy other than malignancy treated with curative intent within less than 5 years. Participants with the following diagnoses represents an exception and may enroll if ≥ 1 year with no evidence of active disease before the first dose of the study drug:
•Locally advanced non-melanoma skin cancers with no current evidence of disease
•Melanoma in situ with no current evidence of disease
•Localized cancer of the prostate with prostate-specific antigen of <1 ng/mL
•Treated or localized well-differentiated thyroid cancer
•Treated cervical carcinoma in situ
•Treated ductal/lobular carcinoma in situ of the breast
•Evidence of uncontrolled, active infection, requiring systemic anti-bacterial, anti-viral or anti-fungal therapy ≤ 10 days prior to administration of cemiplimab and cetuximab. Subjects with known hepatitis B, hepatitis C (HCV), or HIV infection could go on study if the viral load is undetectable at screening.
•Disease or medical conditions that would substantially increase the risk-benefit ratio of participating in the study that include acute myocardial infarction within the last 6 months, unstable angina, uncontrolled diabetes mellitus, significant active infections, and congestive heart failure New York Heart Association Class III-IV
•Female participants who are pregnant or breast-feeding
•Known hypersensitivity to any of the study drugs, the metabolites, or formulation excipient

研究组 & 干预措施

Cemiplimab + Cetuximab

Experimental

Participants will receive cemiplimab and cetuximab together for 6 weeks, and then you will have salvage surgery. Based on how the tumor responds to the study therapy, you may also receive cemiplimab alone for up to 1 year after surgery.

干预措施: Cemiplimab (Drug)

Cemiplimab + Cetuximab

Experimental

干预措施: Cetuximab (Drug)

结局指标

主要结局

Safety and adverse events (AEs)

时间窗: Through study completion; an average of 1 year

Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0

次要结局

未报告次要终点

研究者

发起方

M.D. Anderson Cancer Center

申办方类型

Other

责任方

Sponsor

研究点 (1)

Loading locations...

相似试验

进行中（未招募）

1 期

Cemiplimab Before and After Surgery for the Treatment of High Risk Cutaneous Squamous Cell CancerMetastatic Skin Squamous Cell CarcinomaRecurrent Skin Squamous Cell Carcinoma

NCT04428671Emory University14

暂停

3 期

NCT06568172National Cancer Institute (NCI)420

尚未招募

2 期

The role of post-operative cetuximab-based bioradiotherapy in high risk head and neck carcinomas.Head and neck squamous cell carcinomas

JPRN-UMIN000017634Department of Otolaryngology- Head and Neck Surgery, Hokkaido University Graduate school of Medicine.20

招募中

1 期

Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell CarcinomaCutaneous Squamous Cell CarcinomaMerkel Cell Carcinoma

NCT04975152H. Lee Moffitt Cancer Center and Research Institute36

进行中（未招募）

2 期

A Phase II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy for Immunochemotherapy-resistant Early-stage Triple-negative Breast Cancer (TNBC)Breast Cancer

NCT05675579M.D. Anderson Cancer Center27